Latest California Healthline Stories
Social Media Is Fueling Enthusiasm for New Weight Loss Drugs. Are Regulators Watching?
Online platforms are overflowing with testimonials for GLP-1s. The drugs show promise for inducing weight loss, but many aren’t FDA-approved for that use.
Redes sociales alimentan obsesión por las drogas para bajar de peso, sin hablar de riesgos
La competencia para hacerse con un mercado que podría valer $100.000 millones al año, solo para los fabricantes de medicamentos, ha desencadenado una ola de publicidad que preocupa a las autoridades sanitarias y médicos de todo el mundo.
People With Down Syndrome Are Living Longer, but the Health System Still Treats Many as Kids
The median life expectancy for a U.S. baby born with Down syndrome jumped from about four years in 1950 to 58 years in the 2010s. That’s largely because they no longer can be denied lifesaving care, including surgeries for heart defects. But now, aging adults with Down syndrome face a health system unprepared to care for them.
The Drug Company That Prospered Without Creating Any Drugs
Horizon Therapeutics, which Amgen is acquiring for about $28 billion, grew large by snapping up cheap drugs from other companies, marketing them to perfection, and jacking up prices.
La empresa farmacéutica que prosperó sin crear ni un solo medicamento
Aunque Horizon afirma que ahora tiene 20 fármacos en desarrollo, en sus 15 años de existencia aún no ha obtenido la licencia de un producto de su creación.
Feds Launch Criminal Investigation Into ‘AGGA’ Dental Device and Its Inventor
KFF Health News and CBS News recently reported that multiple lawsuits allege the device has led to grievous injuries to patients’ mouths, resulting in loss of teeth.
As Montana’s Mental Health Crisis Care Crumbles, Politicians Promise Aid
One of Montana’s largest mental health providers has ratcheted back services amid financial troubles, leaving a vacuum. State policymakers have promised more money to aid behavioral health care, but lasting change could be years out.
Doctors’ Lesson for Drug Industry: Abortion Wars Are Dangerous to Ignore
The American Medical Association ducked the abortion issue for years and now sees its members’ professional opinions second-guessed by lawmakers and judges. PhRMA is following the same playbook.
No-Cost Preventive Services Are Now in Jeopardy. Here’s What You Need to Know.
A federal judge’s recent ruling on the Affordable Care Act is by no means the final word. Even parsing its impact is complicated. Here are key issues to watch as the case works its way through the legal system.
KFF Health News' 'What the Health?': The ‘Unwinding’ of Medicaid
As of April 1, states were allowed to begin reevaluating Medicaid eligibility for millions of Americans who qualified for the program during the covid-19 pandemic but may no longer meet the income or other requirements. As many as 15 million people could lose health coverage as a result. Meanwhile, the Medicare Hospital Insurance Trust Fund is projected to stay solvent until 2031, its trustees reported, taking some pressure off of lawmakers to finally fix that program’s underlying financial weaknesses. Alice Miranda Ollstein of Politico, Rachel Roubein of The Washington Post, and Amy Goldstein of The Washington Post join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Daniel Chang, who reported the latest KHN-NPR “Bill of the Month” feature about a child not yet old enough for kindergarten whose medical bill landed him in collections.